

Breast Cancer Treatment

Reference Number: F4725
Date of Response: 19/08/2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

Royal Devon's Eastern FOI Office Response

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) – **0 patients**
- Abemaciclib + Fulvestrant – **7 patients**
- Atezolizumab + Nab-paclitaxel/Paclitaxel --* **<5 patients**
- Neratinib – **0 patients**
- Olaparib – **0 patients**
- Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) – **45 patients**
- Palbociclib + Fulvestrant – **12 patients**
- Pembrolizumab – **0 patients**
- Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) – **11 patients**
- Ribociclib + Fulvestrant -- * **<5 patients**
- Sacituzumab Govitecan -- * **<5 patients**
- Trastuzumab as a single agent or in combination – **65 patients**
- Trastuzumab emtansine – **8 patients**
- Transtuzumab deruxtecan -- * **<5 patients**
- Any other active systemic anti-cancer therapy – **156 patients**

***≤5 In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles.**